618 McKesson Corporation $MCK Shares Purchased by Calamos Advisors LLC

Calamos Advisors LLC lifted its stake in McKesson Corporation (NYSE:MCK) by 2.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,607 shares of the company’s stock after purchasing an additional 618 shares during the period. Calamos Advisors LLC’s holdings in McKesson were worth $26,133,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Rosenberg Matthew Hamilton increased its position in McKesson by 2.8% in the third quarter. Rosenberg Matthew Hamilton now owns 406 shares of the company’s stock worth $347,000 after buying an additional 11 shares in the last quarter. Avail Investment Partners LLC raised its stake in shares of McKesson by 1.7% in the third quarter. Avail Investment Partners LLC now owns 662 shares of the company’s stock worth $566,000 after buying an additional 11 shares during the period. Commonwealth Financial Services LLC lifted its position in shares of McKesson by 3.8% during the 3rd quarter. Commonwealth Financial Services LLC now owns 304 shares of the company’s stock valued at $260,000 after buying an additional 11 shares in the last quarter. Stephens Inc. AR lifted its position in shares of McKesson by 0.8% during the 1st quarter. Stephens Inc. AR now owns 1,581 shares of the company’s stock valued at $1,368,000 after buying an additional 12 shares in the last quarter. Finally, WealthPLAN Partners LLC grew its stake in shares of McKesson by 0.4% during the 3rd quarter. WealthPLAN Partners LLC now owns 3,190 shares of the company’s stock valued at $2,724,000 after acquiring an additional 12 shares during the period. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

Insider Transactions at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the completion of the transaction, the chief accounting officer owned 521 shares in the company, valued at $464,445.45. This trade represents a 17.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 650 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $1,102.96, for a total value of $716,924.00. Following the transaction, the executive vice president owned 4,414 shares of the company’s stock, valued at $4,868,465.44. This represents a 12.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 2,462 shares of company stock valued at $2,511,106. 0.06% of the stock is currently owned by insiders.

McKesson Stock Performance

Shares of McKesson stock traded down $11.21 on Friday, hitting $1,060.79. 812,129 shares of the company traded hands, compared to its average volume of 691,239. McKesson Corporation has a 52 week low of $723.68 and a 52 week high of $1,121.50. The business has a 50-day simple moving average of $938.13 and a 200 day simple moving average of $868.12. The stock has a market capitalization of $123.68 billion, a P/E ratio of 27.28, a price-to-earnings-growth ratio of 1.99 and a beta of 0.27.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, beating the consensus estimate of $10.72 by $0.96. The company had revenue of $110.96 billion during the quarter, compared to analysts’ expectations of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. McKesson’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period last year, the company posted $9.86 earnings per share. Research analysts expect that McKesson Corporation will post 45.26 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, December 1st. McKesson’s payout ratio is 9.67%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MCK. TD Cowen increased their target price on shares of McKesson from $1,006.00 to $1,200.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings upgraded shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, September 4th. Wells Fargo & Company increased their price objective on shares of McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 11th. Mizuho raised their price objective on shares of McKesson from $905.00 to $1,020.00 and gave the company a “neutral” rating in a research report on Tuesday, October 20th. Finally, Citigroup lifted their target price on shares of McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,026.18.

McKesson Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.